Sorin Visanica

发表

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

B. Leber, A. M. de Almeida, G. Pica, 2019, Leukemia & lymphoma.

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

J. Hernández-Rivas, A. Stamatoullas, P. Fenaux, 2018, British journal of haematology.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2012, Blood.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2011, Blood.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

S. Chevret, E. Wattel, P. Fenaux, 2012, Haematologica.

in MDS patients treated with AZA. Its prognostic value may be further improved by specific scoring systems established for AZA treatment such as the one we described previously.3

A. Stamatoullas, B. Quesnel, P. Fenaux, 2017 .

PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.

C. Bastard, E. Lippert, S. Taviaux, 2012, Leukemia research.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

P. Fenaux, M. Sébert, L. Adès, 2011, Leukemia research.

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

A. Stamatoullas, B. Quesnel, P. Fenaux, 2012 .

Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program

A. Stamatoullas, B. Quesnel, E. Wattel, 2010 .

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

J. Cayuela, P. Cony-Makhoul, H. Bruzzoni-Giovanelli, 2022, Pharmaceutics.

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

S. Chevret, P. Fenaux, M. Sébert, 2010 .

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

E. Wattel, P. Fenaux, M. Sébert, 2009 .

Acute monocytic leukemia with coexpression of minor BCR–ABL1 and PICALM–MLLT10 fusion genes along with overexpression of HOXA9

E. Macintyre, E. Delabesse, A. Staal, 2006, Genes, chromosomes & cancer.

Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with Chronic Myeloid Leukemia - Final results of the randomized Optim imatinib study: Co-028

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2015 .

Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation.

J. Stoltz, D. Bensoussan, V. Decot, 2012, Bio-medical materials and engineering.